Ad-hoc | 18 September 2003 19:31

Carl Zeiss Meditec AG english

Capital increase successfully concluded Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– -NOT FOR DISTRIBUTION IN THE USA, CANADA AND JAPAN- Capital increase successfully concluded Subscription price of EUR 9.70 – Free float increased to about 26 per cent In a public offer in Germany and a private international placement (no placement in the USA, Canada and Japan), a total of 2,583,329 Carl Zeiss Meditec AG shares were placed today within a few hours. The orderbook was oversubscribed by more than two times. The shares stem from a capital increase in which subscription rights were excluded; they were placed at a subscription price of EUR 9.70 by Commerzbank (lead manager and bookrunner) and Bankhaus Sal. Oppenheim (Co-Manager) using an accelerated bookbuilding. The total value of the transaction was about EUR 25 million. The increased share capital of Carl Zeiss Meditec is now EUR 28,416,629. In order to increase the free float, Carl Zeiss Group, the majority shareholder of the company, accepted a dilution of its stake and did not subscribe to any shares in the transaction. The Carl Zeiss Meditec free float has now therefore risen to about 26 percent. Furthermore, a greenshoe of 400,000 shares is being made available from the shares held by the Carl Zeiss Group. Contact: Carl Zeiss Meditec AG, Jens Brajer/Investor Relations, Goeschwitzer Str. 51 -52, D-07745 Jena, Phone +49 (0)3641-220-105, Fax: +49 (0)3641-220-117, E-Mail: investors@meditec.zeiss.com end of ad-hoc-announcement (c)DGAP 18.09.2003 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: About Carl Zeiss Meditec Carl Zeiss Meditec AG (ISIN: DE000531379) is one of the world’s leading solution providers in the field of ophthalmology. Its product line includes diagnostic and therapy systems for all four main fields of application on the eye: refraction, cataract, glaucoma and retinal disorders. Carl Zeiss Meditec AG has strong, long-established distribution channels across the globe. Its presence in the USA is of particular importance. Here, the corporation occupies a dominant market position with its own subsidiary, Carl Zeiss Meditec, Inc. in Dublin, California (formerly Humphrey Systems). Carl Zeiss Meditec AG has also had its own subsidiary in Japan, the largest market after USA. Considerable growth potential exists in the market for ophthalmic products. As a market leader with broad technological competency and innovative product applications, Carl Zeiss Meditec AG will continue to expand its position in future. Legal notes This announcement is made purely for information purposes and does not represent an offer or an invitation to submit an offer for the purchase of shares in Carl Zeiss Meditec AG, or a promotion of a share offer. The distribution of this announcement and the offer and sale of Carl Zeiss Meditec AG shares may be restricted in certain jurisdictions. Persons receiving or reading this announcement should inform themselves with regard to these restrictions and observe them. This announcement does not represent an offer, or an invitation to submit an offer for the purchase of shares in Carl Zeiss Meditec AG, or promotion of a share offer in the USA. The offer and the sale of Carl Zeiss Meditec AG shares have not been, and will not be, registered in accordance with the U.S. Securities Act of 1933 in its current version, and, in accordance with the U.S. Securities Act, they may not be offered or sold without registration or exemption from the registration requirements. ——————————————————————————– WKN: 531370; ISIN: DE0005313704; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 181931 Sep 03